As of 2025-04-23, the EV/EBITDA ratio of OncoCyte Corp (OCX) is -4.43. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. OCX's latest enterprise value is 74.67 mil USD. OCX's TTM EBITDA according to its financial statements is -16.86 mil USD. Dividing these 2 quantities gives us the above OCX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.0x - 10.8x | 9.8x |
| Forward P/E multiples | 15.2x - 30.0x | 19.5x |
| Fair Price | (8.68) - (6.12) | (8.37) |
| Upside | -401.3% - -312.5% | -390.5% |
| Date | EV/EBITDA |
| 2025-04-21 | -4.43 |
| 2025-04-17 | -4.36 |
| 2025-04-16 | -4.34 |
| 2025-04-15 | -4.53 |
| 2025-04-14 | -4.37 |
| 2025-04-11 | -4.26 |
| 2025-04-10 | -4.46 |
| 2025-04-09 | -4.55 |
| 2025-04-08 | -4.21 |
| 2025-04-07 | -4.36 |
| 2025-04-04 | -4.24 |
| 2025-04-03 | -4.50 |
| 2025-04-02 | -4.55 |
| 2025-04-01 | -4.63 |
| 2025-03-31 | -4.73 |
| 2025-03-28 | -4.99 |
| 2025-03-27 | -5.01 |
| 2025-03-26 | -4.94 |
| 2025-03-25 | -4.70 |
| 2025-03-24 | -5.19 |
| 2025-03-21 | -5.31 |
| 2025-03-20 | -5.14 |
| 2025-03-19 | -5.48 |
| 2025-03-18 | -5.68 |
| 2025-03-17 | -5.82 |
| 2025-03-14 | -5.89 |
| 2025-03-13 | -6.11 |
| 2025-03-12 | -5.97 |
| 2025-03-11 | -6.48 |
| 2025-03-10 | -6.62 |
| 2025-03-07 | -6.16 |
| 2025-03-06 | -5.72 |
| 2025-03-05 | -5.68 |
| 2025-03-04 | -4.96 |
| 2025-03-03 | -4.26 |
| 2025-02-28 | -4.29 |
| 2025-02-27 | -3.90 |
| 2025-02-26 | -3.91 |
| 2025-02-25 | -3.82 |
| 2025-02-24 | -4.01 |
| 2025-02-21 | -4.04 |
| 2025-02-20 | -4.16 |
| 2025-02-19 | -4.23 |
| 2025-02-18 | -4.12 |
| 2025-02-14 | -3.89 |
| 2025-02-13 | -3.58 |
| 2025-02-12 | -3.80 |
| 2025-02-11 | -3.56 |
| 2025-02-10 | -3.05 |
| 2025-02-07 | -2.95 |